In 2017, the report found all low- and middle-income countries could access entecavir, which is used to treat hepatitis B, and all but two could access the infection treatment tenofovir.
Despite a decrease in the median price of generic tenofovir, from $208 per year of treatment in 2004 to $32 in 2016, treatment rates are still low, the CDC found.
“Taking advantage of reductions in price of antivirals active against [hepatitis B virus] infection could further increase access to treatment,” the agency wrote. “Regular analysis of the hepatitis B treatment care cascade can assist in monitoring progress toward [hepatitis B virus] elimination goals.”
More articles on clinical leadership and infection control:
Health officials praise Kentucky for hep A outbreak response
New hand hygiene data collection process uses Google
44 states affected by salmonella outbreak tied to live poultry
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
